Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
"The ImageStreamX is the result of focused technology development based on both a broad market research study and more than five years of very close work with our customer base," remarked William E. Ortyn, Amnis' co-founder and Chief Operating Officer. "If early market response is a good indicator of ultimate product success, then it appears this work was right on the mark," he added.
"Pre-sales of the ImageStreamX have greatly exceeded our expectations, particularly given the current economic climate," said David Basiji, Ph.D., Amnis' President and Chief Executive Officer. "These sales results are due to the dramatic performance increase combined with the greater affordability and modularity of the new ImageStreamX, which allows the instrument to fit into a much wider range of labs and budgets," explained Basiji. Mr. Ortyn added, "The ImageStreamX has many of the attributes necessary to perform in the clinical market place. Over the next several months we look forward to releasing a wide array of options and applications kits to further enhance product capabilities."
Can synthetic data boost fairness in medical imaging AI?